AxoGen (NASDAQ:AXGN) Director Amy Mcbride Wendell Sells 43,684 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 43,684 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $29.31, for a total transaction of $1,280,378.04. Following the sale, the director owned 93,826 shares in the company, valued at approximately $2,750,040.06. The trade was a 31.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

AxoGen Trading Up 7.1%

Shares of AXGN stock opened at $31.44 on Thursday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.64 and a current ratio of 4.09. AxoGen, Inc. has a 52-week low of $9.22 and a 52-week high of $34.24. The stock has a fifty day simple moving average of $24.09 and a two-hundred day simple moving average of $17.35. The firm has a market capitalization of $1.45 billion, a PE ratio of -627.80 and a beta of 1.06.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.03. The business had revenue of $60.08 million during the quarter, compared to the consensus estimate of $56.90 million. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%. On average, analysts predict that AxoGen, Inc. will post -0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AXGN has been the subject of a number of research analyst reports. Canaccord Genuity Group lifted their price objective on shares of AxoGen from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, December 5th. Citigroup reaffirmed a “market outperform” rating on shares of AxoGen in a report on Thursday, October 30th. Raymond James Financial reissued an “outperform” rating and issued a $36.00 price target on shares of AxoGen in a report on Thursday, December 4th. JMP Securities set a $34.00 target price on AxoGen in a research report on Thursday, October 30th. Finally, Jefferies Financial Group boosted their target price on AxoGen from $29.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.56.

Institutional Trading of AxoGen

A number of hedge funds and other institutional investors have recently made changes to their positions in AXGN. Future Financial Wealth Managment LLC acquired a new stake in shares of AxoGen in the 3rd quarter valued at approximately $27,000. Aquatic Capital Management LLC increased its stake in shares of AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 1,269 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of AxoGen in the 3rd quarter valued at about $43,000. Tower Research Capital LLC TRC increased its position in AxoGen by 189.9% during the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock worth $55,000 after buying an additional 3,327 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in AxoGen during the 3rd quarter valued at $64,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.